Integra Lifesciences Holdings (IART) Total Liabilities (2009 - 2026)

Integra Lifesciences Holdings (IART) has 18 years of Total Liabilities data on file, last reported at $2.5 billion in Q1 2026.

• For the quarter ending Q1 2026, Total Liabilities changed 0.27% year-over-year to $2.5 billion; the trailing twelve-month figure through Mar 2026 stood at $2.5 billion (changed 0.27% YoY), and the FY2025 full-year result was $2.6 billion, up 2.66% from the prior year.
• Total Liabilities declined to $2.5 billion in Q1 2026, from $2.6 billion in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $2.6 billion in Q2 2025 to a low of $2.1 billion in Q1 2022.
• A 5-year average of $2.3 billion and a median of $2.5 billion in 2024 frame the typical range for Total Liabilities.
• Across the five-year window, Total Liabilities declined 7.03% in 2022 and increased 21.29% in 2024, its largest moves.
• Tracing IART's Total Liabilities over 5 years: stood at $2.1 billion in 2022, then gained by 5.21% to $2.2 billion in 2023, then gained by 13.58% to $2.5 billion in 2024, then grew by 2.66% to $2.6 billion in 2025, then slipped by 0.91% to $2.5 billion in 2026.
• Business Quant data shows IART's Total Liabilities at $2.5 billion in Q1 2026, $2.6 billion in Q4 2025, and $2.6 billion in Q3 2025.